Logo image of CERE

CEREVEL THERAPEUTICS HOLDING (CERE) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CERE - US15678U1280 - Common Stock

44.96 USD
+0.33 (+0.74%)
Last: 7/31/2024, 8:26:40 PM
44.97 USD
+0.01 (+0.02%)
After Hours: 7/31/2024, 8:26:40 PM
Fundamental Rating

2

CERE gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. The financial health of CERE is average, but there are quite some concerns on its profitability. CERE is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

CERE had negative earnings in the past year.
In the past year CERE has reported a negative cash flow from operations.
In the past 5 years CERE always reported negative net income.
In the past 5 years CERE always reported negative operating cash flow.
CERE Yearly Net Income VS EBIT VS OCF VS FCFCERE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -100M -200M -300M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of -40.85%, CERE is in line with its industry, outperforming 57.32% of the companies in the same industry.
With a Return On Equity value of -81.58%, CERE perfoms like the industry average, outperforming 49.83% of the companies in the same industry.
Industry RankSector Rank
ROA -40.85%
ROE -81.58%
ROIC N/A
ROA(3y)-34.02%
ROA(5y)N/A
ROE(3y)-56.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CERE Yearly ROA, ROE, ROICCERE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

CERE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CERE Yearly Profit, Operating, Gross MarginsCERE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

5

2. Health

2.1 Basic Checks

CERE has more shares outstanding than it did 1 year ago.
The debt/assets ratio for CERE has been reduced compared to a year ago.
CERE Yearly Shares OutstandingCERE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 50M 100M 150M
CERE Yearly Total Debt VS Total AssetsCERE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 6.22 indicates that CERE is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 6.22, CERE belongs to the best of the industry, outperforming 81.88% of the companies in the same industry.
CERE has a Debt/Equity ratio of 0.60. This is a neutral value indicating CERE is somewhat dependend on debt financing.
CERE has a worse Debt to Equity ratio (0.60) than 74.04% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Altman-Z 6.22
ROIC/WACCN/A
WACCN/A
CERE Yearly LT Debt VS Equity VS FCFCERE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

CERE has a Current Ratio of 10.22. This indicates that CERE is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of CERE (10.22) is better than 77.87% of its industry peers.
CERE has a Quick Ratio of 10.22. This indicates that CERE is financially healthy and has no problem in meeting its short term obligations.
CERE has a Quick ratio of 10.22. This is in the better half of the industry: CERE outperforms 77.87% of its industry peers.
Industry RankSector Rank
Current Ratio 10.22
Quick Ratio 10.22
CERE Yearly Current Assets VS Current LiabilitesCERE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 200M 400M 600M 800M 1B

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CERE have decreased by -7.48% in the last year.
EPS 1Y (TTM)-7.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

CERE is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.74% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y3.92%
EPS Next 2Y-3.42%
EPS Next 3Y-4.42%
EPS Next 5Y12.74%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CERE Yearly Revenue VS EstimatesCERE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 1B 2B 3B
CERE Yearly EPS VS EstimatesCERE Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4 -4 6 8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CERE reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CERE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CERE Price Earnings VS Forward Price EarningsCERE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CERE Per share dataCERE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

A cheap valuation may be justified as CERE's earnings are expected to decrease with -4.42% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-3.42%
EPS Next 3Y-4.42%

More info and screens

0

5. Dividend

5.1 Amount

CERE does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CEREVEL THERAPEUTICS HOLDING

NASDAQ:CERE (7/31/2024, 8:26:40 PM)

After market: 44.97 +0.01 (+0.02%)

44.96

+0.33 (+0.74%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-30 2024-07-30/bmo
Earnings (Next)10-30 2024-10-30/bmo
Inst Owners3.18%
Inst Owner Change0%
Ins Owners4.59%
Ins Owner Change0%
Market Cap8.19B
Revenue(TTM)N/A
Net Income(TTM)-460.47M
Analysts52.86
Price Target44.27 (-1.53%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.15%
Min EPS beat(2)-25.25%
Max EPS beat(2)-17.05%
EPS beat(4)2
Avg EPS beat(4)-8.03%
Min EPS beat(4)-25.25%
Max EPS beat(4)5.41%
EPS beat(8)4
Avg EPS beat(8)-6.57%
EPS beat(12)5
Avg EPS beat(12)-5.52%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2.99%
EPS NY rev (1m)0%
EPS NY rev (3m)-0.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 14.51
P/tB 14.51
EV/EBITDA N/A
EPS(TTM)-2.73
EYN/A
EPS(NY)-2.86
Fwd EYN/A
FCF(TTM)-2.04
FCFYN/A
OCF(TTM)-2.01
OCFYN/A
SpS0
BVpS3.1
TBVpS3.1
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -40.85%
ROE -81.58%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-34.02%
ROA(5y)N/A
ROE(3y)-56.87%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.6
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 63.94%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.22
Quick Ratio 10.22
Altman-Z 6.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)179.4%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-7.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-8.96%
EPS Next Y3.92%
EPS Next 2Y-3.42%
EPS Next 3Y-4.42%
EPS Next 5Y12.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-24.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.19%
EBIT Next 3Y-8.84%
EBIT Next 5Y15.59%
FCF growth 1Y-70.23%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-74.97%
OCF growth 3YN/A
OCF growth 5YN/A

CEREVEL THERAPEUTICS HOLDING / CERE FAQ

Can you provide the ChartMill fundamental rating for CEREVEL THERAPEUTICS HOLDING?

ChartMill assigns a fundamental rating of 2 / 10 to CERE.


Can you provide the valuation status for CEREVEL THERAPEUTICS HOLDING?

ChartMill assigns a valuation rating of 0 / 10 to CEREVEL THERAPEUTICS HOLDING (CERE). This can be considered as Overvalued.


What is the profitability of CERE stock?

CEREVEL THERAPEUTICS HOLDING (CERE) has a profitability rating of 1 / 10.


What is the earnings growth outlook for CEREVEL THERAPEUTICS HOLDING?

The Earnings per Share (EPS) of CEREVEL THERAPEUTICS HOLDING (CERE) is expected to grow by 3.92% in the next year.